- Home
- ILAG vs CANF Comparison
ILAG vs CANF Comparison
Compare ILAG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILAG | CANF |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.7M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ILAG | CANF |
|---|---|---|
| Price | $2.10 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 4.4K | ★ 613.1K |
| Earning Date | 04-27-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | $290,391.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.17 |
| 52 Week High | $7.19 | $10.40 |
Technical Indicators
Market Signals| Indicator | ILAG | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 39.28 |
| Support Level | $2.04 | $0.59 |
| Resistance Level | $3.31 | $4.74 |
| Average True Range (ATR) | 0.21 | 0.22 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 11.10 | 14.52 |
Price Performance
Historical ComparisonAbout ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.